The stock of Hikma Pharmaceuticals Plc (LON:HIK) is a huge mover today! The stock decreased 0.13% or GBX 2.15 on November 18, hitting GBX 1661.85. About 712,600 shares traded hands. Hikma Pharmaceuticals Plc (LON:HIK) has declined 27.97% since April 21, 2016 and is downtrending. It has underperformed by 32.40% the S&P500.
The move comes after 5 months negative chart setup for the GBX 3.84B company. It was reported on Nov, 18 by Barchart.com. We have GBX 1562.14 PT which if reached, will make LON:HIK worth GBX 230.40 million less.
Hikma Pharmaceuticals Plc (LON:HIK) Ratings Coverage
Out of 14 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 12 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 86% are positive. Hikma Pharmaceuticals PLC has been the topic of 96 analyst reports since July 29, 2015 according to StockzIntelligence Inc. J.P. Morgan maintained Hikma Pharmaceuticals Plc (LON:HIK) rating on Monday, March 14. J.P. Morgan has “Overweight” rating and GBX 2500 price target. The firm earned “Buy” rating on Wednesday, March 16 by Panmure Gordon. The rating was maintained by AlphaValue on Thursday, January 7 with “Add”. As per Wednesday, August 19, the company rating was maintained by Jefferies. The stock has “Buy” rating given by Jefferies on Tuesday, July 5. The company was maintained on Thursday, May 12 by Cantor Fitzgerald. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, September 9 report. Citigroup reinitiated the stock with “Buy” rating in Thursday, March 24 report. The firm has “Hold” rating given on Wednesday, August 19 by Shore Capital. JP Morgan maintained Hikma Pharmaceuticals Plc (LON:HIK) rating on Tuesday, January 19. JP Morgan has “Overweight” rating and GBX 2700 price target.
Another recent and important Hikma Pharmaceuticals Plc (LON:HIK) news was published by Fool.Co.Uk which published an article titled: “Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after …” on August 24, 2016.
Hikma Pharmaceuticals Plc is a pharmaceutical company. The company has a market cap of 3.84 billion GBP. The Firm develops, makes and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa region and Europe. It has a 24.62 P/E ratio. The Company’s divisions include Branded, Injectables, Generics and Others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.